Merck Sharp & Dohme


Zuellig Pharma


A. Menarini
Concise Prescribing Info
Per mL Betamethasone dipropionate 5 mg, betamethasone disodium phosphate 2 mg
Adjunctive treatment of acute & chronic corticosteroid-responsive disorders.
Dosage/Direction for Use
Systemic therapy Initially 1-2 mL deep IM inj & repeated as necessary. SLE or status asthmaticus Initially 2 mL. Dermatological conditions 1 mL IM. Symptomatic control of bronchial asthma, hay fever, allergic rhinitis & bronchitis 1-2 mL. Acute or chronic bursitis 1-2 mL IM & repeated as necessary. Acute subdeltoid, subacromial, oleocranon & prepatellar bursitis 1-2 mL intrabursal inj. Acute tenosynovitis, tendinitis & peritendinitis 1 inj, may be repeated in chronic cases. IA Pain, soreness & stiffness relief in RA & OA 0.5-2 mL. Large joints 1-2 mL. Medium joints 0.5-1 mL. Small joints 0.25-0.5 mL. Intralesional treatment 0.2 mL/cm2, not to exceed 1 mL wkly. Bursitis under heloma durum or molle, synovial cyst & Morton's neuralgia (metatarsalgia) 0.25-0.5 mL. Bursitis under calcaneal spur, over hallux rigidus & over digiti quinti varus, tenosynovitis, cuboid periostitis 0.5 mL. Acute gouty arthritis 0.5-1 mL.
Hypersensitivity to betamethasone or other corticosteroids. Systemic fungal infection.
Special Precautions
Hypersensitivity. Not for IV or SC use; epidural inj. Not as replacement for conventional therapy. Not to be inj into unstable joints, infected areas or intravertebral spaces & directly into tendon substance. Avoid local inj into previously infected joint. Idiopathic thrombocytopenia purpura, TB, ocular herpes simplex, hypothyroidism. Existing emotional instability or psychotic tendencies. Nonspecific ulcerative colitis, impending perforation, abscesses or pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; HTN; osteoporosis; myasthenia gravis. May mask signs of infection. Visual disturbance. Not to undertake immunization procedures eg, smallpox vaccinations. Avoid exposure to chickenpox or measles. Dietary salt restriction & K supplementation. Avoid abrupt w/drawal. High-dose & long-term use. Cirrhosis. Renal insufficiency. Women of childbearing potential. Pregnancy & lactation. Growth & development in infants & childn. Not to be used in neonates. Avoid in childn <2 yr.
Adverse Reactions
Fluid & electrolyte disturbances, musculoskeletal, GI, dermatologic, neurologic, endocrine, ophth, metabolic & psychiatric disorders, anaphylactoid or hypersensitivity & hypotensive or shock-like reactions.
Drug Interactions
Enhanced metabolism w/ phenobarb, phenytoin, rifampin, ephedrine. Excessive corticosteroid effects w/ estrogen. Increased risk of systemic corticosteroid effects w/ strong CYP3A4 inhibitors. Enhanced hypokalemia w/ K-depleting diuretics. Enhanced possibility of arrythmias or digitalis toxicity w/ cardiac glycosides. Enhanced K depletion by amphotericin B. Increased or decreased anticoagulant effects w/ coumarin-type anticoagulants. Increased occurrence or severity of GI ulceration w/ NSAIDs or alcohol. Decreased blood salicylate conc. Inhibited response to somatotropin. False -ve result in nitro-blue tetrazolium test.
ATC Classification
H02AB01 - betamethasone ; Belongs to the class of glucocorticoids. Used in systemic corticosteroid preparations.
Diprospan inj (vial)
5 mL x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in